Greatbatch, Inc. (GB) Showcases Medical Device Evolution to Investors and Analysts
3/19/2013 10:04:50 AM
FRISCO, Texas--(BUSINESS WIRE)--Greatbatch, Inc. (NYSE:GB) today updated institutional investors and research analysts in New York City regarding its strategic evolution. The company is progressing from strictly a developer of components and sub-assemblies to an organization also capable of developing complete medical devices for OEM customers. Speaking at the Millennium Broadway Hotel, President & Chief Executive Officer Thomas J. Hook, Senior Vice President & Chief Financial Officer Michael Dinkins and Algostim, LLC President Scott Drees focused on three topics: how the company’s core business is driving organic growth and financial performance; Algostim, its innovative, internally developed spinal cord stimulation (SCS) system which is nearing completion; and 2013 financial guidance with long-term plans to drive profitable growth.